937 related articles for article (PubMed ID: 29444376)
1. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
Bissonnette R; Luger T; Thaçi D; Toth D; Lacombe A; Xia S; Mazur R; Patekar M; Charef P; Milutinovic M; Leonardi C; Mrowietz U
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1507-1514. PubMed ID: 29444376
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
Bissonnette R; Luger T; Thaçi D; Toth D; Messina I; You R; Guana A; Fox T; Papavassilis C; Gilloteau I; Mrowietz U
Br J Dermatol; 2017 Oct; 177(4):1033-1042. PubMed ID: 28580579
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study.
Okubo Y; Ohtsuki M; Morita A; Yamaguchi M; Shima T; Tani Y; Nakagawa H;
J Dermatol; 2019 Mar; 46(3):186-192. PubMed ID: 30672623
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Langley RG; Sofen H; Dei-Cas I; Reich K; Sigurgeirsson B; Warren RB; Paul C; Szepietowski JC; Tsai TF; Hampele I; You R; Charef P; Papavassilis C
Br J Dermatol; 2023 Feb; 188(2):198-207. PubMed ID: 36763857
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
10. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
Puig L; Augustin M; Blauvelt A; Gottlieb AB; Vender R; Korman NJ; Thaçi D; Zhao Y; Gilloteau I; Sherif B; Williams N; Guana A; Lebwohl MG
J Am Acad Dermatol; 2018 Apr; 78(4):741-748. PubMed ID: 29066271
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE).
Mrowietz U; Leonardi CL; Girolomoni G; Toth D; Morita A; Balki SA; Szepietowski JC; Regnault P; Thurston H; Papavassilis C;
J Am Acad Dermatol; 2015 Jul; 73(1):27-36.e1. PubMed ID: 25982539
[TBL] [Abstract][Full Text] [Related]
13. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.
Mrowietz U; Bachelez H; Burden AD; Rissler M; Sieder C; Orsenigo R; Chaouche-Teyara K
J Am Acad Dermatol; 2019 May; 80(5):1344-1352. PubMed ID: 30716404
[TBL] [Abstract][Full Text] [Related]
14. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
Bagel J; Duffin KC; Moore A; Ferris LK; Siu K; Steadman J; Kianifard F; Nyirady J; Lebwohl M
J Am Acad Dermatol; 2017 Oct; 77(4):667-674. PubMed ID: 28780364
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE).
Thaçi D; Humeniuk J; Frambach Y; Bissonnette R; Goodman JJ; Shevade S; Gong Y; Papavassilis C;
Br J Dermatol; 2015 Sep; 173(3):777-87. PubMed ID: 25823958
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.
Sticherling M; Mrowietz U; Augustin M; Thaçi D; Melzer N; Hentschke C; Kneidl J; Sieder C; Reich K
Br J Dermatol; 2017 Oct; 177(4):1024-1032. PubMed ID: 28580646
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Augustin M; Reich K; Yamauchi P; Pinter A; Bagel J; Dahale S; You R; Bruin G; Djimopoulos J; Paguet B; Charef P; Patekar M; Keefe D
Br J Dermatol; 2022 Jun; 186(6):942-954. PubMed ID: 34981829
[TBL] [Abstract][Full Text] [Related]
18. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.
Ohtsuki M; Morita A; Igarashi A; Imafuku S; Tada Y; Fujita H; Fujishige A; Yamaguchi M; Teshima R; Tani Y; Nakagawa H
J Dermatol; 2017 Oct; 44(10):1105-1111. PubMed ID: 28543617
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
Lee MG; Huang YH; Lee JH; Lee SC; Kim TG; Aw DC; Bao W; Dee CMA; Guana A; Tsai TF
J Dermatol; 2019 Sep; 46(9):752-758. PubMed ID: 31342560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
